Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
147 hedge funds and large institutions have $1.36B invested in Eagle Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 51 increasing their positions, 49 reducing their positions, and 22 closing their positions.
216% more call options, than puts
Call options by funds: $12.2M | Put options by funds: $3.85M
18% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 22
4% more capital invested
Capital invested by funds: $1.31B → $1.36B (+$57.9M)
4% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 49
1% less funds holding
Funds holding: 149 → 147 (-2)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$89.7M |
| 2 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$53.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$17M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$15.6M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$9.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$39.5M |
| 2 |
PAI
ProQuest Associates IV
Naples,
Florida
|
-$22.3M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$15.6M |
| 4 |
CM
Castleark Management
Chicago,
Illinois
|
-$9.24M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.89M |
EGRX Hedge Fund Activity: Q1 2017 in Review
147 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q1 2017, worth a combined $1.36B — up 4.4% from $1.31B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new EGRX positions and 22 closed out — a net gain of 4 holders — while 51 added to existing stakes and 49 trimmed.
The largest buyer was BlackRock, adding an estimated $89.7M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $39.5M sold.
- 147 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q1 2017, down from 149 in Q4 2016.
- Funds reported $1.36B of Eagle Pharmaceuticals, Inc. stock for Q1 2017, up 4.4% quarter-over-quarter.
- 26 funds opened new Eagle Pharmaceuticals, Inc. positions in Q1 2017 and 22 closed out, a net change of +4 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q1 2017 was BlackRock, an estimated $89.7M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q1 2017 was Perceptive Advisors, an estimated $39.5M sold.
Based on aggregated 13F filings for Q1 2017.